Objective-To investigate the mechanism of calcium antagonist mediated cytoprotection against the damaging effects of adrenaline in vivo on cardiac myocytes and human endothelial cells from the umbilical vein.
The calcium channel blockers have an established role in clinical practice related to their effect on smooth muscle contractility. Evidence suggests that other functions of this class of drug are likely to be of equal interest. Many of the calcium antagonists inhibit the formation of atherosclerosis, and cause its regression in hyperlipidaemic animal models. ' Verapamil inhibited cataract formation in alloxan-diabetic rats in a tissue where there are no vascular smooth muscle cells.2 Methoxy-verapamil inhibited the myocardial injury produced by injection of catecholamines.3 The mechanism by which calcium channel blockers confer this myocardial protection is not certain. The initial hypothesis was that calcium influx into the myocyte would deplete the intracellular pool of adenosine triphosphate thus provoking an energy collapse and leading to cell death. 45 Blockage of the calcium channels should therefore prevent this depletion of adenosine triphosphate. This hypothesis is inconsistent with the fact that adenosine triphosphate depletion does not cause myocardial damage.6 When isolated rat cardiomyocytes maintained in a medium with a high calcium concentration were treated with isoprenaline or the calcium ionophore A 23187 there was only a transient effect on ATP production.78 It is possible9 "' that the damage produced in the myocardium by adrenaline or isoprenaline is mediated by free radicals. This hypothesis arose from the observation that catecholamines had no direct effect on cardiac myocytes maintained in vitro4 whereas plasma taken from rats 30 minutes after injection of adrenaline was profoundly cytotoxic to these cells. " We studied the effect of calcium blockers on the oxidative stress-mediated cytotoxicity of plasma from catecholamine treated animals. The calcium blockers chosen were methoxyverapamil (D600) and nifedipine, which belong to the phenethylamine and the dihydropiridine groups of calcium antagonists respectively. The effects of each of these in the same model system would show whether these chemically different compounds have a common mode of action in inhibiting catecholamine induced myocardial injury.
Glutathione is the main source of reducing equivalents for protecting the cell against oxidative stress and the main cellular mechanisms for protection against free radical attack are the glutathione peroxidases and glutathione transferase. '1-13 
Results

SECRETED GLUTATHIONE
Treatment of isolated cardiomyocytes with plasma taken from animals given catecholamine considerably increased the secretion of glutathione. The increase started about 15 minutes after the plasma was added to the cells' incubating medium (fig 1) . The removal of the plasma containing medium from the cells and its replacement by fresh incubating medium had no effect on the extracellular accumulation of secreted glutathione which continued. This 0 by implication the degree of oxidative stress was clearly reduced by treatment with the calcium blockers.
REDUCED GLUTATHIONE
The concentration of reduced glutathione in myocytes was greatly decreased by the treatment with the plasma from animals pretreated with adrenaline ( fig 2) . In endothelial cells calcium blockers were also effective in preventing the oxidation of glutathione. Figure 4 Inhibition of release of angiotensin converting enzyme from endothelial cells exposed to "adrenaline plasma" from animals pretreated with calcium antagonists.
3. 
Discussion
Hitherto the best evidence linking calcium antagonists with protection against cardiac injury mediated by free radicals relates to the protection they confer against the damage induced by doxorubicin,2' where the role offree radicals in the injury is well established. There is evidence from other published reports that calcium antagonists can act as antioxidants. [22] [23] [24] The evidence we present provides further confirmation that adrenaline damage to cardiac myocytes is largely caused by oxidative stress. More importantly it also shows that calcium antagonists largely prevent this stress. Much less glutathione was lost from cells when that plasma came from animals pretreated with calcium blockers. The cytotoxicity of "adrenaline plasma" could not be reproduced when adrenaline was added (in vitro) to the plasma of control (untreated) animals, even at concentrations up to one hundred times higher than would be expected to be found normally in rat plasma.
The protective effect of calcium antagonists in this study was obtained not by treatment of the target cells themselves but by pretreating the animals from which the "adrenaline plasma" was derived. These results suggest therefore that in this model calcium antagonists act by preventing the generation in vivo of the cytotoxic plasma borne compounds that result from the administration of adrenaline.
A role for calcium antagonists in inhibiting the generation of free radicals might serve to protect native low density lipoprotein within the arterial intima from undergoing the oxidative modification that seems to be important in the development of atherosclerotic lesions.25 This might be an explanation for the inhibition of new lesion formation that has been described in animals and now in humans.2"28 Equally, calcium antagonists may prevent endothelial damage and thus influence the progression of atherosclerosis.
